Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Cash Flows From Operating Activities
Loss from continuing operations	$ (97,361)	$ (71,350)	$ (26,657)
Loss from discontinued operations	(19,147)	(7,103)	(454)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization	25,564	32,592	7,566
Impairment of indefinite lived intangible asset	12,200
Share-based compensation	8,216	8,458	13,365
Accretion/(amortization) of investment premiums/discounts	295		(27)
Accretion of interest on long-term debt	4,302	3,596
Provision for bad debt	787	1,392	239
Provision for write-down of inventories	5,255	2,129	1,698
Loss on disposal of property and equipment	1,013	296	312
Gain on previously held equity interest in Morphormics	(662)
Loss from deconsolidation of a variable interest entity	3,442
Provision for deferred income taxes	947	495	63
Changes in assets and liabilities:
Restricted cash	(1,163)	1,605
Accounts receivable	10,858	(9,162)	8,698
Inventories	(5,147)	11,927	(4,321)
Prepaid expenses and other assets	5,166	2,886	(1,126)
Deferred cost of revenue	(4,005)	2,080	7,586
Accounts payable	(1,140)	(21,425)	10,662
Accrued liabilities	(18,525)	(10,538)	9,768
Customer advances	(659)	(7,044)	(909)
Deferred revenue	3,587	20,887	(14,060)
Net cash provided by (used in) operating activities	(66,177)	(38,279)	12,403
Cash Flows From Investing Activities
Purchases of property and equipment , net	(15,126)	(10,769)	(4,022)
Purchases of intangible assets	(232)
Purchases of investments	(102,403)		(100,710)
Sales and maturities of investments			206,414
Acquisition of businesses, net of cash acquired	(3,861)	(1,384)	(70,265)
Net cash provided by (used in) investing activities	(121,622)	(12,153)	31,417
Cash Flows From Financing Activities
Proceeds from issuance of common stock	7,455	4,449	5,601
Proceeds from debt, net of costs	110,462	96,100
Net cash provided by financing activities	117,917	100,549	5,601
Effect of exchange rate changes on cash and cash equivalents	(309)	(2,519)	1,051
Net increase (decrease) in cash and cash equivalents	(70,191)	47,598	50,472
Cash and cash equivalents at beginning of period	143,504	95,906	45,434
Cash and cash equivalents at end of period	73,313	143,504	95,906
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	2,000	1,198	1,392
Cash paid for interest	3,750	1,875
Non-cash financing activity:
Fair value of common stock issued and vested options and restricted stock awards assumed in connection with acquisition of TomoTherapy			$ 73,845